Search research articles
Contact Us
Filters
Showing results (171-180 of 388) with videos related to
Page
of 39
Sort By:
International Journal of Molecular Medicine
|
January 15, 2003
Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone
Maria Teresa Valle, Camillo Porta, Anna Maria Megiovanni, et al.
Anticancer Research
|
March 14, 2007
Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells
Camillo Porta, Lucia Bonomi, Beatrice Lillaz, et al.
Anticancer Research
|
November 14, 2013
A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer
Chiara Paglino, Giuseppe Procopio, Roberto Sabbatini, et al.
European Urology
|
July 29, 2015
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma
Camillo Porta, Martin E Gore, Brian I Rini, et al.
Anticancer Research
|
July 31, 2013
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study
Fable Zustovich, Lorenza Landi, Giuseppe Lombardi, et al.
Cancer Treatment Reviews
|
March 18, 2022
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations
Roberto Iacovelli, Chiara Ciccarese, Giuseppe Procopio, et al.
Oncology Reports
|
November 21, 2008
Immunological stress in kidney cancer patients undergoing either open nephrectomy or nephron-sparing surgery: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells
Camillo Porta, Lucia Bonomi, Beatrice Lillaz, et al.
Tumori
|
April 4, 2015
Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers
Lorenza Rimassa, Armando Santoro, Bruno Daniele, et al.
Lancet (London, England)
|
July 22, 2022
The multispeciality approach to the management of localised kidney cancer
Grant D Stewart, Tobias Klatte, Laura Cosmai, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2016
Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis
Bernard Escudier, Vincent Molinie, Sergio Bracarda, et al.
Page
of 39
Search research articles
Search
Showing results (171-180 of 388) with videos related to
Sort By:
Page
of 39
International Journal of Molecular Medicine
|
January 15, 2003
Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone
Maria Teresa Valle, Camillo Porta, Anna Maria Megiovanni, et al.
Anticancer Research
|
March 14, 2007
Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells
Camillo Porta, Lucia Bonomi, Beatrice Lillaz, et al.
Anticancer Research
|
November 14, 2013
A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer
Chiara Paglino, Giuseppe Procopio, Roberto Sabbatini, et al.
European Urology
|
July 29, 2015
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma
Camillo Porta, Martin E Gore, Brian I Rini, et al.
Anticancer Research
|
July 31, 2013
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study
Fable Zustovich, Lorenza Landi, Giuseppe Lombardi, et al.
Cancer Treatment Reviews
|
March 18, 2022
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations
Roberto Iacovelli, Chiara Ciccarese, Giuseppe Procopio, et al.
Oncology Reports
|
November 21, 2008
Immunological stress in kidney cancer patients undergoing either open nephrectomy or nephron-sparing surgery: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells
Camillo Porta, Lucia Bonomi, Beatrice Lillaz, et al.
Tumori
|
April 4, 2015
Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers
Lorenza Rimassa, Armando Santoro, Bruno Daniele, et al.
Lancet (London, England)
|
July 22, 2022
The multispeciality approach to the management of localised kidney cancer
Grant D Stewart, Tobias Klatte, Laura Cosmai, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2016
Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis
Bernard Escudier, Vincent Molinie, Sergio Bracarda, et al.
Page
of 39